Drug Trial Radar · NCT06940141
Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
160
Actual
Start
Aug 8, 2025
Primary completion
Jul 17, 2026
Study completion Aug 10, 2026
Sponsor
- Lead sponsor
- Connect Biopharm LLCIndustry
- Sponsor type
- Industry
- First posted
- Apr 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, randomized, multicenter study in adult and adolescent participants with asthma and type 2 inflammation
Conditions
- Asthma Acute
Interventions
Rademikibart in prefilled syringeCombination product
Participants receive 600 mg (4mL) of rademikibart administered subcutaneously.
Matching placebo in prefilled syringeDrug
Participants receive 4mL of placebo matched to rademikibart administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment failure rate within 28 days after randomizationTime frame: 28 days
Locations
58 sites in 6 countries. Site status is shown where the registry gives one.
Leland Stanford Junior University, Stanford Hospital
Palo Alto, California
Amicis Research Center
Valencia, California
Nemours Children's Hospital - DE
Wilmington, Delaware
Nemours Children's Health
Jacksonville, Florida
Pharmax Research of South Florida, Inc.
Miami, Florida
Columbus Clinical Services, LLC
Miami, Florida
Nemours Children's Health, Lake Nona
Orlando, Florida
Health Synergy Clinical Research, LLC
West Palm Beach, Florida
Primeway Clinical Research Group
Fayetteville, Georgia
Pivotal Research Solutions
Stonecrest, Georgia
University of Iowa
Iowa City, Iowa
University of Kansas Medical Center
Kansas City, Kansas
Allergy & Asthma Specialists, P.S.C.
Owensboro, Kentucky
Chesapeake Clinical Research, Inc.
White Marsh, Maryland
Washington University School of Medicine
St Louis, Missouri
The Ohio State University Wexner Medical Center
Columbus, Ohio
Clinical Research of Rock Hill
Rock Hill, South Carolina
Inquest Clinical Research
Baytown, Texas
Premier Pulmonary Critical Care and Sleep Medicine
Denison, Texas
DCT- McAllen Primary Care Research, LLC dba Discovery Clinical Trials
McAllen, Texas
Vermont Lung Center
Colchester, Vermont
INSARES
Mendoza, Argentina
Centro de Diagnostico y Rehabilitación S.A. -CEDIR
Santa Fe, Argentina
STAT Research
Caba, Buenos Aires, Argentina
Hospital Italiano de Buenos Aires
Caba, Buenos Aires, Argentina
Investigaciones en Alergias y Enfermoedades Respiratorias (InAER)
Caba, Buenos Aires, Argentina
Instituto Ave Pulmo-Fundacion Enfisema
Mar del Plata, Buenos Aires, Argentina
Hospital Universitario Austral
Pilar, Buenos Aires, Argentina
CEMER - Centro Medico de Enfermedades Respiratorias
San Juan Bautista, Buenos Aires, Argentina
Centro respiratorio Infantil
Rosario, Santa Fe Province, Argentina
INECO Neurociencias Oroño
Rosario, Santa Fe Province, Argentina
Investigaciones en Patologias Respiratorias SRL
San Miguel de Tucumán, Tucumán Province, Argentina
The Canberra Hospital
Garran, Australian Capital Territory, Australia
Campbelltown Hospital
Campbelltown, New South Wales, Australia
St. Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia
St George Hospital, South Eastern Sydney Local Health District
Kogarah, New South Wales, Australia
Queensland Children's Hospital
South Brisbane, Queensland, Australia
Bendigo Health
Bendigo, Victoria, Australia
JSC "National Center for Lung Health"
Tbilisi, Georgia
LLC "Israel-Georgian Medical Research Clinic Healthycore"
Tbilisi, Georgia
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.